
IDEAYA Biosciences, Inc. — Investor Relations & Filings
IDEAYA Biosciences, Inc. is a clinical-stage precision medicine oncology company focused on the discovery, development, and commercialization of targeted therapeutics for cancer. The company's primary scientific approach is synthetic lethality, an emerging class of precision medicine that targets cancer cells based on specific genetic alterations. IDEAYA develops potential first-in-class and best-in-class therapies for patient populations selected using molecular diagnostics. Its integrated platform combines capabilities in target and biomarker discovery with the development of small molecule and protein degrader therapeutics to address unmet needs in cancer treatment.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| S-3ASR - IDEAYA Biosciences, Inc. (0001676725) (Filer) | 2026-05-05 | English | |
| 8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer) | 2026-05-05 | English | |
| 8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer) | 2026-04-13 | English | |
| 8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer) | 2026-04-09 | English | |
| SCHEDULE 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject) | 2026-03-27 | English | |
| 4 - IDEAYA BIOSCIENCES, INC. (0001676725) (Filer) | 2026-03-03 | English |
Browse filings by year
10 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 41528732 | S-3ASR - IDEAYA Biosciences, Inc. (0001676725) (Filer) | 2026-05-05 | English | ||
| 41325620 | 8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer) | 2026-05-05 | English | ||
| 34403025 | 8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer) | 2026-04-13 | English | ||
| 33898483 | 8-K - IDEAYA Biosciences, Inc. (0001676725) (Filer) | 2026-04-09 | English | ||
| 33061067 | SCHEDULE 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject) | 2026-03-27 | English | ||
| 32896471 | 4 - IDEAYA BIOSCIENCES, INC. (0001676725) (Filer) | 2026-03-03 | English | ||
| 32896472 | 8-K - IDEAYA BIOSCIENCES, INC. (0001676725) (Filer) | 2026-02-17 | English | ||
| 31258355 | 10-K Filing | 2026-02-17 | English | ||
| 31258163 | SCHEDULE 13G/A Filing | 2026-02-17 | English | ||
| 19424576 | SCHEDULE 13G/A - IDEAYA Biosciences, Inc. (0001676725) (Subject) | 2026-02-12 | English | ||
| 31258199 | 4 Filing | 2026-02-02 | English | ||
| 31258190 | 4 Filing | 2026-02-02 | English | ||
| 31258189 | 4 Filing | 2026-02-02 | English | ||
| 31258159 | 4 Filing | 2026-02-02 | English | ||
| 31258156 | 4 Filing | 2026-02-02 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
AC Immune SA
Biopharmaceutical firm developing precision medicine for ne…
|
ACIU | CH | Manufacturing |
|
Aclaris Therapeutics, Inc.
Clinical-stage biopharmaceutical company developing drugs f…
|
ACRS | US | Manufacturing |
|
Acrivon Therapeutics, Inc.
Clinical-stage biopharma using proteomics to develop precis…
|
ACRV | US | Manufacturing |
|
ACRUX LIMITED
Develops and commercializes topical and transdermal drug de…
|
ACR | AU | Manufacturing |
|
Acticor Biotech
Develops treatments for thrombotic diseases, focusing on ac…
|
ALACT | FR | Manufacturing |
|
Actinium Pharmaceuticals, Inc.
Clinical-stage company developing targeted radiotherapies f…
|
ATNM | US | Manufacturing |
|
ACTUATE THERAPEUTICS, INC.
Clinical-stage biopharma developing therapies for cancers w…
|
ACTU | US | Manufacturing |
|
AcuCort AB
Develops user-friendly drug formulations for severe and acu…
|
ACUC | SE | Manufacturing |
|
Acumen Pharmaceuticals, Inc.
Clinical-stage biopharma developing targeted therapies for …
|
ABOS | US | Manufacturing |
|
Acurx Pharmaceuticals, Inc.
Clinical-stage biopharma developing a new class of antibiot…
|
ACXP | US | Manufacturing |
IDEAYA Biosciences, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31547/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31547 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31547 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31547 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31547}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for IDEAYA Biosciences, Inc. (id: 31547)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.